FDMT Q1 2023 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$298,000-75.6% YoY

Gross Profit

-$22M-7420.8% margin

Operating Income

-$30M-10102.7% margin

Net Income

-$29M-9624.8% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

-76.1%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$29M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$244M

Total Liabilities

$25M

Stockholders' Equity

$219M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$298,000	$1M	-75.6%
Gross Profit	-$22M	-$18M	-21.8%
Operating Income	-$30M	-$26M	-14.1%
Net Income	-$29M	-$26M	-8.9%

Geographic Segments

NETHERLANDS

$295,00099%

UNITED STATES

$3,0001%